GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of GM1 for preventing cognitive impairment related to
whole brain radiotherapy in breast cancer patients with brain metastases. And explore the
clinical and molecular parameter for predicting severe cognitive impairment induced by WBRT
and gaining benefit from GM1.
Primary Endpoint: the change of Hopkins Verbal and Learning Test-Revised Delayed
Recall,HVLT-R DR,before and after WBRT Secondary ENDPOINT: the change of Alzheimer's Disease
Assessment Scale-Cognitive，ADAS-Cog before and after WBRT;severe cognitive impairment
percentage and onset time; Design:204 patients will be randomly assigned to exp.group,102
cases,and 102 cases of control group.